PDCD5 Antibody
| Code | Size | Price |
|---|
| PSI-5019-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5019-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
PDCD5 Antibody: DCHT, PASK, SPAK, DCHT, Ste-20-related kinase
Application Note:
PDCD5 antibody can be used for detection of PDCD5 by Western blot at 2.5 μg/mL. Antibody can also be used for immunocytochemistry starting at 5 μg/mL.
Antibody validated: Western Blot in human samples and Immunocytochemistry in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples and Immunocytochemistry in human samples. All other applications and species not yet tested.
Background:
PDCD5 Antibody: Programmed cell death 5 (PDCD5), a human apoptosis-related protein, is thought to play an early and universal role in apoptosis. PDCD5 is widely expressed and is upregulated in cells undergoing apoptosis, where it translocates rapidly from the cytoplasm to the nucleus. PDCD5 has a compact core structure of low flexibility with two mobile alpha-helices at N-terminal and a flexible unstructured C-terminal region. The charged residues are crucial for the ability of apoptosis-promoting and cell translocation of the protein. PDCD5 can facilitate apoptosis and enhance TAJ/TROY-induced paraptosis-like cell death. PDCD5 may play a dual role in the Tip60 pathway. It interacts with Tip60 and functions as a Tip60 co-activator to promote apoptosis. The nucleotide polymorphisms in the 5'-upstream region of?PDCD5 affect promoter activity and the susceptibility of a Chinese population to develop chronic myelogenous leukemia and may represent a novel tumor suppressor gene influencing lung cancer.
Background References:
- Liu H, Wang Y, Zhang Y, et al.?TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. ?Biochem. Biophys. Res. Commun.1999; 254:203-10.?
- Chen Y, Sun R, Han W, et al. Nuclear translocation of PDCD5 (TFAR19): an early signal for apoptosis? FEBS Lett.2001; 509:191-6.
- Yao H, Xu L, Feng Y, et al. Structure-function correlation of human programmed cell death 5 protein. Arch. Biochem. Biophys.2009 Apr 7.?
- Wang Y, Li X, Wang L, et al. An alternative form of paraptosis-like cell death triggered by TAJ/TROY and enhanced by PDCD5 overexpression.? J. Cell Sci.2004; 117:1525-32.?
Buffer:
PDCD5 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (100%)
Immunogen:
PDCD5 antibody was raised against a 13 amino acid synthetic peptide from near the amino terminus of human PDCD5.
The immunogen is located within the first 50 amino acids of PDCD5.
The immunogen is located within the first 50 amino acids of PDCD5.
NCBI Gene ID #:
27347
NCBI Official Name:
serine threonine kinase 39 (STE20/SPS1 homolog, yeast)
NCBI Official Symbol:
STK39
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 14 kDa
Observed: 21 kDa
Observed: 21 kDa
Protein Accession #:
CAG33215
Protein GI Number:
115430252
Purification:
PDCD5 Antibody is affinity chromatography purified via peptide column.
Research Area:
Neuroscience
Swissprot #:
Q9UEW8
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | PDCD5 Peptide | PSI-5019P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|